159 related articles for article (PubMed ID: 35266888)
1. Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer.
Alandağ C; Karaman E; Yüce E
Anticancer Drugs; 2022 Apr; 33(4):389-393. PubMed ID: 35266888
[TBL] [Abstract][Full Text] [Related]
2. Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Int J Clin Oncol; 2023 Sep; 28(9):1183-1190. PubMed ID: 37322220
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
4. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China.
Qu W; Liu Z; Chen X; Liu B; Zhao Y; Yan H; Qu X; Li S; Zang A; Sun Y; Zhu L; Zhou A
BMC Cancer; 2024 Jan; 24(1):22. PubMed ID: 38166647
[TBL] [Abstract][Full Text] [Related]
8. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study.
Wang H; Liu W; Zhao Y; Hu H; Zhang B; Yang S
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e291-e299. PubMed ID: 36572661
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data.
Calvo-García A; Abánades MP; Ruíz-García S; Román ABF; Fernández JL; García BC; Terciado CH; Álvarez RS; Solis RM; Marin BH; Diez PT; Baladrón AM; Bosch RC
Oncology (Williston Park); 2022 Dec; 36(12):732-738. PubMed ID: 36548097
[TBL] [Abstract][Full Text] [Related]
14. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
15. Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer.
Kato T; Kudo T; Kagawa Y; Murata K; Ota H; Noura S; Hasegawa J; Tamagawa H; Ohta K; Ikenaga M; Miyazaki S; Komori T; Uemura M; Nishimura J; Hata T; Matsuda C; Satoh T; Mizushima T; Ohno Y; Yamamoto H; Doki Y; Eguchi H
Sci Rep; 2023 Feb; 13(1):2331. PubMed ID: 36759648
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
17. Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
Hsu HC; Huang KC; Chen WS; Jiang JK; Yang SH; Wang HS; Chang SC; Lan YT; Lin CC; Lin HH; Huang SC; Cheng HH; Yang TS; Chen CC; Chao Y; Teng HW
Sci Rep; 2021 Jul; 11(1):15370. PubMed ID: 34321583
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study.
Goktas Aydin S; Kavak EE; Topcu A; Bayramgil A; Akgul F; Kahraman S; Aykan MB; Altıntas YE; Helvaci K; Urun Y; Bilici A; Seker M; Sendur MAN; Olmez OF; Acikgoz O; Cicin I
Biomol Biomed; 2023 Nov; 23(6):1089-1095. PubMed ID: 37289436
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
20. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
